Responses
Regular and young investigator award abstracts
Cellular therapies
114 Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing
Compose a Response to This Article
Other responses
No responses have been published for this article.
